Amylin, Takeda halt obesity drug Phase 2 study PBR Staff Writer

Amylin Pharmaceuticals and Takeda Pharmaceutical have voluntarily halted the ongoing Phase 2 study of investigational combination therapy pramlintide/metreleptin for the treatment of obesity. Pramlintide acetate is a synthetic analog of the natural hormone amylin, a neurohormone secreted by the pancreas that is known to play a role in the regulation of appetite, food intake and postprandial glucose concentrations.Amylin and Takeda have suspended clinical activities to investigate a new antibody-related laboratory finding with metreleptin treatment in two patients who participated in a previously completed clinical study of obesity.However, Amylin confirmed that the suspension of the ongoing Phase 2 study does not affect the company's lipodystrophy development program investigating the use of metreleptin to treat diabetes and/or hypertriglyceridemia (high levels of triglycerides in the bloodstream) in patients with rare forms of lipodystrophy.